Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Soleno Therapeutics

Request full access

Develops and commercializes novel therapeutics for rare genetic disorders, with a lead FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome

Redwood City, United StatesFounded 1999Biotech & Life Sciences

About Soleno Therapeutics

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative treatments for rare diseases. The company primarily focuses on patients suffering from Prader-Willi syndrome (PWS) and other rare endocrine disorders. Soleno's lead product candidate, DCCR (Diazoxide Choline Extended Release) tablets, is an oral medication designed for once-daily use. This product has received Orphan Drug Designation in both the United States and Europe, and it has been designated a Fast Track development program by the FDA, highlighting its potential to address significant unmet medical needs.

Soleno operates in the biopharmaceutical market, targeting a niche segment of rare diseases. The company's business model revolves around advancing its research and development pipeline to bring effective treatments to market. Revenue generation is anticipated through the commercialization of its lead product, DCCR, upon regulatory approval. The company serves a specialized client base, including patients, families, and healthcare providers dealing with rare endocrine disorders.

Soleno's commitment to making a positive impact on patients' lives is evident in its focus on advancing promising research and its dedication to diversity as an equal opportunity employer. The company is supported by a robust leadership team and board of directors with extensive experience in life sciences and investment management.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014
Employees
177
Open positions
7
Dealroom signal
88.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, Orphan Drug Designation, Rare Diseases, Verified Thoroughbreds, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit May 2026 $2.9B $2.9B Neurocrine Biosciences ↗
POST IPO EQUITY✓Other financing Jul 2025 $200M — Undisclosed ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Soleno Therapeutics website traffic

Latest recorded traffic for Soleno Therapeutics is 4.9K monthly website visits, down 67.3% over the last three months. Soleno Therapeutics's team grew 11.3% over the past year.

Latest monthly visits4.9K 3-month web change-67.3% 1-year team growth+11.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Soleno Therapeutics in the Redwood City ecosystem

Live from Dealroom

The Soleno Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later8 investors entered at this stage

  • Abingworth
  • Adage Capital
  • Commodore Capital
  • Frazier Healthcare Partners
  • Nantahala Capital Management
  • Perceptive Advisors
  • Woodline Partners
  • Oxford Finance

Other known investors2 additional known investors

  • Neurocrine Biosciences
  • Vivo Capital
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Redwood City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Soleno Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Soleno Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.